NO20091576L - Sammensetninger av TRL-ligander og antiviraler - Google Patents

Sammensetninger av TRL-ligander og antiviraler

Info

Publication number
NO20091576L
NO20091576L NO20091576A NO20091576A NO20091576L NO 20091576 L NO20091576 L NO 20091576L NO 20091576 A NO20091576 A NO 20091576A NO 20091576 A NO20091576 A NO 20091576A NO 20091576 L NO20091576 L NO 20091576L
Authority
NO
Norway
Prior art keywords
antivirals
compositions
ligands
trl
trl ligands
Prior art date
Application number
NO20091576A
Other languages
English (en)
Inventor
Eugen Uhlmann
Harald Debelak
Jorg Vollmer
Marion Jurk
Robert L Bratzler
Alain Vicari
Original Assignee
Coley Pharmaceutical Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical Group Ltd filed Critical Coley Pharmaceutical Group Ltd
Publication of NO20091576L publication Critical patent/NO20091576L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Sammendrag Oppfinnelsen relaterer til fremgangsmåter og produkter for behandlingen av viral infeksjon ved å benytte en kombinasjon av anti-virale virkemidler og TLR ligander. Oppfinnelsen relaterer også til screening assays, assosierte produkter, kits, og in vitro fremgangsmåter.
NO20091576A 2006-09-27 2009-04-21 Sammensetninger av TRL-ligander og antiviraler NO20091576L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84740806P 2006-09-27 2006-09-27
PCT/US2007/021030 WO2008039538A2 (en) 2006-09-27 2007-09-27 Compositions of tlr ligands and antivirals

Publications (1)

Publication Number Publication Date
NO20091576L true NO20091576L (no) 2009-05-27

Family

ID=39199060

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091576A NO20091576L (no) 2006-09-27 2009-04-21 Sammensetninger av TRL-ligander og antiviraler

Country Status (11)

Country Link
US (1) US20100189772A1 (no)
EP (1) EP2068912A2 (no)
JP (1) JP2010504982A (no)
KR (1) KR20090057468A (no)
CN (1) CN101541965A (no)
AU (1) AU2007300378A1 (no)
BR (1) BRPI0719445A2 (no)
CA (1) CA2664156A1 (no)
MX (1) MX2009003403A (no)
NO (1) NO20091576L (no)
WO (1) WO2008039538A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
EP2368431A1 (en) 2002-04-04 2011-09-28 Coley Pharmaceutical GmbH Immunostimulatory G,U-containing oligoribonucleotides
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
UA88457C2 (ru) 2003-10-30 2009-10-26 Коли Фармасьютикал Гмбх Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CA2630738C (en) 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010088395A2 (en) * 2009-01-30 2010-08-05 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
JP6698069B2 (ja) * 2015-03-20 2020-05-27 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
BR112020018209A2 (pt) * 2018-03-07 2020-12-29 Emory University Composições farmacêuticas, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e para tratar ou prevenir um coronavírus humano, coronavírus sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus da chicungunha, vírus ross river, rsv, vírus influenza a, vírus influenza b, vírus tacaribe, vírus pichinde, vírus junin, vírus da febre lassa, vírus da cariomeningite linfocitária, vírus da febre rift valley, vírus punta toro, vírus lacrosse, vírus maporal, vírus heartland, e vírus da síndrome de trombocitopenia de febre severa, poliovírus, vírus de coxsackie, infecção de norovírus ou enterovírus em um paciente

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
EP2368431A1 (en) * 2002-04-04 2011-09-28 Coley Pharmaceutical GmbH Immunostimulatory G,U-containing oligoribonucleotides
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US8119684B2 (en) * 2003-12-30 2012-02-21 Dana-Farber Cancer Institute, Inc. Thiophene derivatives for up-regulating HLA-DM activity
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
EA200801045A1 (ru) * 2005-10-12 2008-10-30 Кэнсер Рисерч Текнолоджи Лтд. Способы и композиции для лечения иммунных нарушений
CA2630738C (en) * 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides

Also Published As

Publication number Publication date
KR20090057468A (ko) 2009-06-05
CA2664156A1 (en) 2008-04-03
JP2010504982A (ja) 2010-02-18
US20100189772A1 (en) 2010-07-29
MX2009003403A (es) 2009-04-09
WO2008039538A3 (en) 2008-08-07
WO2008039538A2 (en) 2008-04-03
CN101541965A (zh) 2009-09-23
EP2068912A2 (en) 2009-06-17
AU2007300378A1 (en) 2008-04-03
BRPI0719445A2 (pt) 2013-12-10

Similar Documents

Publication Publication Date Title
NO20091576L (no) Sammensetninger av TRL-ligander og antiviraler
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2007134327A3 (en) Neutralizing antibodies to influenza viruses
MA33198B1 (fr) Anticorps anti-her di-spécifiques
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
NO20084850L (no) MGLUR5 modulatorer I
WO2008127364A3 (en) Antiviral compounds and use thereof
ATE524465T1 (de) 2-carboxy-thiophen-derivate als viruzide
ATE550037T1 (de) Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
BRPI0719008A2 (pt) Inibidores de vírus da hepatite c
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA200702193A1 (ru) Гликозилирование белков
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application